Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Aug;50(3):337.
doi: 10.1111/apt.15379.

Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply

Siddharth Singh  1   2 , Vipul Jairath  3   4
Affiliations
Comment

Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply

Siddharth Singh et al. Aliment Pharmacol Ther. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors’ declarations of personal and financial interests are unchanged from those in the original article [ref as in references]

Comment on

References

    1. Paul S, Roblin X Letter: immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol Ther 2019; in press. - PubMed
    1. Singh S, Stitt LW, Zou G, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. Aliment Pharmacol Ther 2019. doi: 10.1111/apt.15214. - DOI - PMC - PubMed
    1. Lobaton T, Ferrante M, Rutgeerts P, Ballet V, van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2015;42:441–51 - PubMed
    1. Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yagnik V, Ananthakrishnan AN. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19:309–15 - PMC - PubMed

Substances